News

As part of the merger, Cornerstone will assume the responsibility to market and promote Cardene I.V. (nicardipine hydrochloride) and Retavase (Reteplase). As part of the agreement Cornerstone has

The vaccine technology mainly focuses on Dengue fever along with other infectious diseases that include Murray River encephalitis and Japanese encephalitis. Under the agreement BioDiem is provided with

Under the collaboration, Tocagen will use MRI Interventions’ ClearPoint neuro intervention system at selected sites in its ongoing investigational clinical trial for the delivery of Toca 511 into

Under the agreement, Patheon will formulate, fill and finish ANX-188 drug product for use in clinical trials, including the Phase 3 study of ANX-188 that ADVENTRX plans to

The FVIII will primarily be used in the treatment of hemophilia A. The only approval now remaining for Taibang’s commercial production of FVIII is the SFDA’s good manufacturing

Neviah Genomics, which is the first company to be funded within the framework of Merck Serono’s Israel Bioincubator program, is expected to focus on the discovery and development

The collaboration will focus on addressing the drug delivery challenges of poorly soluble molecules with limited oral bioavailability by integrating Quotient’s RapidFACTTM clinical manufacture and testing service with

Psion joined forces with Antra ID to offer an integrated solution that deals with shipping, warehousing, distribution, and inventory control. Psion solution features backward compatibility, modularity and field

The company expects to submit European marketing authorization application (MAA) for Heplisav in the third quarter of 2012. Upon approval of the Heplisav BLA, Dynavax also considers submitting